Sudeep Pharma Attracts Strong Investor Demand; Issue Subscribed 93.71 Times

The Initial Public Offering of Sudeep Pharma was subscribed a massive 93.71 times on the final day of bidding.

The issue received bids of 99,00,86,575 shares against the offered 1,05,64,926 equity shares, at a price band of ₹563-593, according to the data available on the stock exchanges.

Qualified Institutional Buyer Portion and Non-Institutional Investors Portion were subscribed 213.1 times and 116.7 times respectively, whereas Retail Portion was subscribed 15.65 times. 

The issue kicked off for subscription on Friday, November 21, 2025 and closed for subscription on Tuesday, November 25, 2025.

ICICI Securities and IIFL Capital Services Ltd are the book-running lead manager; and MUFG Intime India Private Limited is the registrar of the offer.

Company Information

The company is a technology-led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and is dedicated to contributing to the global healthcare ecosystem. The company leverages its inhouse developed technologies for processes such as encapsulation, spray drying, granulation, trituration, liposomal preparations and blending in an effort to drive innovation in our operations. 

It has established a presence in both, domestic and international markets, including key regions such as the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific. The company is one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors, in terms of production capacity with a combined annual available manufacturing capacity of 72,246 metric tons, as of June 30, 2025 (Source: F&S Report). As of the same date, one of its manufacturing Facilities have been approved by the United States Food and Drug Administration (USFDA) for the manufacture of mineral-based ingredients. 

The company’s revenue from operations during the June 2025 quarter was Rs 124.9 crore and its net profit was Rs 28.4 crore.

The company’s revenue from operations was Rs 502 crore during FY 25 vis-à-vis Rs 428.7 crore during FY 23. The company’s net profit was Rs 137 crore during FY 25 vis-à-vis Rs 60.4 crore during FY 23

 

The table below shows subscription data for all the categories of investors:

Sudeep Pharma Limited Last updated on 25 Nov 2025 | 05:18:00 PM Sr.No. Category No.of shares offered / reserved No. of shares bid for No. of times of total meant for the category 1 Qualified Institutional Buyers (QIBs) 30,18,550 64,31,88,450 213.08 1(a) Foreign Institutional Investors (FIIs) - 18,92,40,350 - 1(b) Domestic Financial Institutions(Banks/ Financial Institutions(FIs)/ Insurance Companies) - 25,76,58,675 - 1(c) Mutual Funds - 2,86,45,875 - 1(D) Others - 16,76,43,550 - 2 Non Institutional Investors(NIIS) 22,63,913 26,42,36,925 116.72 2.1 Non Institutional Investors(Bid amount of more than Ten Lakh Rupees) 15,09,276 20,36,19,700 134.91 2.1(a) Corporates - 15,44,025 - 2.1(b) Individuals (Other than RIIs) - 19,18,60,350 - 2.1(c) Others - 1,02,15,325 - 2.2 Non Institutional Investors(Bid amount of more than Two Lakh Rupees and upto 10 lakh rupees) 7,54,637 6,06,17,225 80.33 2.2(a) Corporates - 1,22,950 - 2.2(b) Individuals (Other than RIIs) - 5,77,54,875 - 2.2(c) Others - 27,39,400 - 3 Retail Individual Investors (RIIs) 52,82,463 8,26,61,200 15.65 3(a) Cut Off - 6,79,40,975 - 3(b) Price Bids - 1,47,20,225 - 4 Employee Reserved - - - 4(a) Employee (Cut off) - - - 4(b) Employee (Price) - - - 5 Reservation PortionShareholder - - - 5(a) RPS (Cut off) - - - 5(b) RPS (Price) - - - Total 1,05,64,926 99,00,86,575 93.71